Kiniksa Pharmaceuticals, Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNSA research report →
Companywww.kiniksa.com
Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
- CEO
- Sanj K. Patel
- IPO
- 2018
- Employees
- 315
- HQ
- Hamilton, BM
Price Chart
Valuation
- Market Cap
- $4.08B
- P/E
- 56.85
- P/S
- 5.41
- P/B
- 6.86
- EV/EBITDA
- 38.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.63%
- Op Margin
- 12.36%
- Net Margin
- 9.69%
- ROE
- 13.26%
- ROIC
- 9.56%
Growth & Income
- Revenue
- $677.56M · 60.09%
- Net Income
- $59.01M · 236.61%
- EPS
- $0.80 · 233.33%
- Op Income
- $77.22M
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $59.87
- 52W Low
- $25.70
- 50D MA
- $49.33
- 200D MA
- $42.12
- Beta
- 0.17
- Avg Volume
- 735.19K
Get TickerSpark's AI analysis on KNSA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Paolini John F. | other | 58,424 |
| May 1, 26 | Paolini John F. | sell | 37,327 |
| May 1, 26 | Paolini John F. | sell | 21,097 |
| May 1, 26 | Paolini John F. | other | 58,424 |
| May 1, 26 | Patel Sanj K | other | 48,565 |
| May 1, 26 | Patel Sanj K | other | 48,565 |
| May 1, 26 | Patel Sanj K | sell | 48,565 |
| Apr 28, 26 | Patel Sanj K | other | 51,750 |
| Apr 28, 26 | Patel Sanj K | other | 431,904 |
| Apr 28, 26 | Patel Sanj K | sell | 74,635 |
Our KNSA Coverage
We haven't published any research on KNSA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KNSA Report →